A Multiplex Snapback Primer System for the Enrichment and Detection of JAK2 V617F and MPL W515L/K Mutations in Philadelphia-Negative Myeloproliferative Neoplasms

被引:5
|
作者
Wu, Zhiyuan [1 ,2 ]
Zhang, Yunqing [3 ]
Zhang, Xinju [1 ]
Xu, Xiao [1 ]
Kang, Zhihua [4 ]
Li, Shibao [4 ]
Zhang, Chen [2 ]
Su, Bing [5 ]
Guan, Ming [1 ,2 ,4 ]
机构
[1] Fudan Univ, Shanghai Med Coll, Huashan Hosp, Cent Lab, Shanghai 200433, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Huashan Hosp North, Dept Lab Med, Shanghai 200433, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Dermatol, Guangzhou 510275, Guangdong, Peoples R China
[4] Fudan Univ, Shanghai Med Coll, Huashan Hosp, Dept Lab Med, Shanghai 200433, Peoples R China
[5] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA
关键词
WORLD-HEALTH-ORGANIZATION; TYROSINE KINASE JAK2; EXON; 10; ESSENTIAL THROMBOCYTHEMIA; SENSITIVE DETECTION; MELTING ANALYSIS; MODIFIED PROBES; TIME; POLYMERASE; DNA;
D O I
10.1155/2014/458457
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A multiplex snapback primer system was developed for the simultaneous detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia chromosome-(Ph-) negative myeloproliferative neoplasms (MPNs). The multiplex system comprises two snapback versus limiting primer sets for JAK2 and MPL mutation enrichment and detection, respectively. Linear-After exponential (LATE) PCR strategy was employed for the primer design to maximize the amplification efficiency of the system. Low ionic strength buffer and rapid PCR protocol allowed for selective amplification of the mutant alleles. Amplification products were analyzed by melting curve analysis for mutation identification. The multiplex system archived 0.1% mutation load sensitivity and <5% coefficient of variation inter-/intra-assay reproducibility. 120 clinical samples were tested by the multiplex snapback primer assay, and verified with amplification refractory system (ARMS), quantitative PCR (qPCR) and Sanger sequencing method. The multiplex system, with a favored versatility, provided the molecular diagnosis of Ph-negative MPNs with a suitable implement and simplified the genetic test process.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms
    Sahin, Ezgi
    Yonal-Hindilerden, Ipek
    Hindilerden, Fehmi
    Aday, Aynur
    Nalcaci, Meliha
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2022, 52 (01) : 150 - 165
  • [22] JAK2 V617F and MPL W515L/K screening in patients with RARS-T and RCMD-RS. A single center study
    Zipperer, E.
    Wulfert, M.
    Germing, U.
    Haas, R.
    Gattermann, N.
    ONKOLOGIE, 2010, 33 : 33 - 34
  • [23] The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders
    Kiladjlan, J. J.
    Casadevall, N.
    Vainchenker, W.
    Fenaux, P.
    PATHOLOGIE BIOLOGIE, 2007, 55 (02): : 85 - 87
  • [24] Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
    Zhang, Shu-Peng
    Li, Hui
    Lai, Ren-Sheng
    ONCOLOGY LETTERS, 2015, 9 (02) : 735 - 738
  • [25] Calr Vs. JAK2 Vs. MPL Mutations in the Progression of Philadelphia-Negative Myeloproliferative Neoplasms
    Bai, Jie
    Sheng, Mengyao
    Xing, Wen
    Bai, Jiaojiao
    Li, Rong
    Shi, Jun
    Zhang, Lei
    Yuan, Weiping
    Yang, Feng-Chun
    Zhou, Yuan
    BLOOD, 2017, 130
  • [26] Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations
    Yang, Hai-Su
    CANCER BIOMARKERS, 2016, 17 (04) : 383 - 389
  • [27] The JAK2 V617F mutation in Philadelphia-negative chronic myeloproliferative disorders (vol 60, pg 1070, 2007)
    Stoj, A.
    Rudzki, Z.
    Stachura, J.
    JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (11) : 1296 - 1296
  • [28] JAK2 V617F mutation detection in chronic myeloproliferative neoplasms by digital PCR
    Waterhouse, M.
    Pfeifer, D.
    Follo, M.
    Bertz, H.
    Finke, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 196 - 196
  • [29] Evidence for JAK V617 but not MPL W515l/K mutations in subsets of acute panmyelosis with myelofibrosis (APMF)
    Schmitt-Graeff, A.
    Kapp-Schwoerer, S.
    Schaub, F.
    Skoda, R.
    HISTOPATHOLOGY, 2008, 53 : 236 - 236
  • [30] Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
    Pietra, Daniela
    Li, Sai
    Brisci, Angela
    Passarnonti, Francesco
    Rumi, Elisa
    Theocharides, Alexandre
    Ferrari, Maurizio
    Gisslinger, Heinz
    Kralovics, Robert
    Cremonesi, Laura
    Skoda, Radek
    Cazzola, Mario
    BLOOD, 2008, 111 (03) : 1686 - 1689